Full-Time

Head of Medical Affairs

Kardigan

Kardigan

201-500 employees

Biotech firm developing cardiovascular medicines

No salary listed

Princeton, NJ, USA

In Person

PharmD, MD

Category
Biology & Biotech

Get referred to Kardigan

See people who can refer or advise you

Requirements
  • MD or PharmD with substantial expertise in cardiovascular disease.
  • For appointment at Vice President, 12+ years of biopharma industry experience, including 5+ years leading Medical Affairs teams or functions.
  • For appointment at Senior Vice President, 15+ years of biopharma industry experience, including prior executive-level leadership of a Medical Affairs function.
  • Proven Medical Affairs leadership in the United States biopharma industry across cardiovascular indications, spanning both small and large organizations, including fast-growing companies.
  • Product launch leadership in new and competitive markets; candidates without a complete launch must have demonstrably equivalent late-stage evidence-generation and launch-readiness leadership.
  • Experience leading core Medical Affairs capabilities, including field medical, medical communications and publications, evidence generation covering health economics and outcomes research and real-world evidence, medical information, and medical governance, with broad knowledge of the regulations and industry codes governing scientific exchange.
  • Scientific rigor and credibility, with the ability to evaluate and debate detailed scientific and clinical issues with confidence and curiosity, both internally and externally.
  • Track record of recruiting, developing, and unifying high-performing teams through growth and organizational change, combining hands-on coaching with clear direction and empowerment.
  • Ability to build trusted cross-functional relationships and scale infrastructure in step with portfolio expansion.
  • Executive presence with strong communication, negotiation, and influencing skills; sound judgment, humility, and high emotional intelligence, including in high-stakes conversations.
  • Ability to articulate a compelling Medical Affairs vision that inspires action internally and externally.
  • Strong patient-centric orientation, ensuring Medical Affairs strategies ultimately serve patients and their families.
Responsibilities
  • Lead, unify, and scale Kardigan’s Medical Affairs organization, positioning the function to drive value for patients, healthcare providers, and the broader business.
  • Develop and execute the Medical Affairs strategy for Kardigan’s prioritized cardiovascular indications in partnership with the Chief Executive Officer and Executive Leadership Team.
  • Ensure Medical Affairs readiness for potential future launches and establish the function as a critical source of scientific insight on key questions raised by Kardigan’s investigational pipeline.
  • Own the Medical Affairs budget, headcount plan, and operating model; build remaining capabilities, including field medical, integrated evidence generation, and medical operations and governance, as the portfolio and organization grow.
  • Lead, develop, and retain the existing Medical Affairs team while recruiting talent to close capability gaps.
  • Establish and strengthen relationships with key opinion leaders, investigators, scientific advisory groups, professional societies, patient advocacy organizations, and other members of the external medical and scientific community.
  • Build cross-functional partnerships with Clinical Development, Commercial, Regulatory, and Safety, bringing the external medical voice into trial design, evidence planning, and portfolio decisions.
  • Lead an integrated evidence-generation strategy spanning health economics and outcomes research, real-world evidence, and epidemiology.
  • Oversee medical and scientific communications, including publication planning, congress strategy, and medical information, to contribute to the scientific literature and support potential future commercialization and patient access.
  • Provide medical input into medical, scientific, and promotional materials, and establish Medical Affairs’ role in the company’s material review process.
  • Establish and maintain the compliance framework governing scientific exchange and external engagement, including advisory boards, investigator-initiated studies, and grants, consistent with applicable regulations and industry codes of practice.
  • Provide hands-on leadership, coaching, and mentorship while empowering the Medical Affairs team to take ownership and deliver results.
Desired Qualifications
  • Collaborative and pragmatic partnership style.
  • Strong communication, negotiation, and influencing skills.
  • Executive presence, sound judgment, humility, and high emotional intelligence.

Kardigan develops medicines to prevent and treat cardiovascular disease. It focuses on discovering and developing multiple cardiovascular therapies at a rapid pace, using deep expertise in heart-health drug development to move candidates from research toward commercialization. Their product approach centers on creating medicines that address heart disease more effectively and earlier in the disease process. Kardigan differentiates itself through a leadership team of seasoned biopharma veterans and a commitment to modernizing how cardiovascular drugs are discovered and developed, aiming to bring therapies to patients faster and more efficiently. The company’s goal is to reduce the global burden of cardiovascular disease by providing safe, effective medicines that prevent progression or cure conditions related to heart health.

Company Size

201-500

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

2023

Get referred to Kardigan

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 IPO raised $460 million gross, lifting cash to $660.7 million.
  • August 2026: KINSHIP-DCM Phase 3 started, while KARDINAL-ASH enrolled its first patient.
  • ESC 2026 presentations and 1H 2027 topline data keep multiple catalysts ahead.

What critics are saying

  • Kardigan reported $116.2 million Q2 2026 losses, burning IPO cash quickly.
  • All three programs need successful 1H 2027 readouts; one failure could erase valuation.
  • No product revenue exists; another financing round before 2028 would dilute shareholders.

What makes Kardigan unique

  • Tassos Gianakakos and Jay Edelberg built MyoKardia’s mavacamten playbook, then Kardigan.
  • Kardigan pairs Prolaio AI with late-stage cardio trials for narrower, faster registrational studies.
  • Danicamtiv, ataciguat, and tonlamarsen target separate unmet cardiovascular niches without approved therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

15%

1 year growth

15%

2 year growth

30%
MarketScreener
Jun 18th, 2026
Kardigan makes strong Nasdaq debut following upsized IPO.

Kardigan makes strong Nasdaq debut following upsized IPO. Kardigan delivered a notable market debut on the Nasdaq, raising $400m in an upsized initial public offering. Shares of the cardiovascular treatment specialist opened at $16.25, above the $16 IPO price, before climbing more than 22% during the session. This performance underscores a resurgence in investor appetite for biotechnology firms boasting advanced clinical programs and robust growth prospects. Published on 06/18/2026 at 03:52 pm EDT Based in Princeton, New Jersey, Kardigan is developing several precision therapies for cardiovascular diseases. Its pipeline notably includes drug candidates danicamtiv, ataciguat, and tonlamarsen. Management has indicated that pivotal data regarding these three programs are expected during the first half of next year. The company was founded by Tassos Gianakakos and Jay Edelberg, two former executives who played key roles in the development of the heart medication mavacamten at MyoKardia, which was acquired by Bristol Myers Squibb for $13bn in 2020. This transaction takes place within a more favorable environment for biotech IPOs following several years defined by tighter access to capital. However, analysts point out that Kardigan may require additional financing in the medium term. The company stated in its regulatory filings that its current resources would not be sufficient to fund operations for at least twelve months without further capital injections, even though the funds raised are intended to accelerate the development of its clinical programs. (C) MarketScreener.com - 2026

IPO Scoop
Jun 18th, 2026
Kardigan

Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums), is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.

StockTitan
Jun 18th, 2026
Kardigan prices upsized $400M IPO at $16 per share on Nasdaq

Kardigan, a clinical-stage precision therapeutics company developing treatments for cardiovascular diseases, has priced its initial public offering of 25 million shares at $16 per share. The offering is expected to generate gross proceeds of $400 million before underwriting discounts and expenses. The company has granted underwriters a 30-day option to purchase an additional 3.75 million shares. Kardigan's shares are expected to begin trading on the Nasdaq Global Market on 18 June 2026 under the ticker symbol "KARD", with the offering closing on 22 June 2026. J.P. Morgan Securities, Jefferies, Leerink Partners and TD Securities are serving as underwriters. Based in South San Francisco and Princeton, Kardigan focuses on developing medicines targeting cardiovascular diseases without approved treatments.

pharmaphorum
Jun 18th, 2026
Heart drug biotech Kardigan raises $400m in upscaled IPO.

Heart drug biotech Kardigan raises $400m in upscaled IPO. Cardiovascular drug developer Kardigan has completed its IPO, and in common with the prevailing trend in Nasdaq listings this year, has raised substantially more than it originally anticipated. The gross proceeds have come in at around $400 million, with 25 million shares sold for $16 apiece, which compares to Kardigan's earlier objective of selling 23.3 million at a range of $14 to $16. The final tally could be increased by another $60 million or so if underwriters take up an option to buy another 3.75 million shares at the final price. The proceeds - which top up cash reserves of around $287 million held by Kardigan at the end of March - will go towards the company's three clinical-stage drug candidates, which are all in late-stage development, along with R&D and general corporate purposes. Between $80 million and $90 million is earmarked for danicamtiv, an oral cardiac myosin activator for dilated cardiomyopathy (DCM) driven by MYH7 and TTN gene variants in genes coding for the sarcomere, the functional unit of muscle tissue. That should allow Kardigan to complete an ongoing phase 2b trial and the start of phase 3 development, according to its IPO prospectus. The company has allocated the same amount to ataciguat, a once-daily, oral soluble guanylate cyclase (sGC) activator for calcific aortic valve stenosis (CAVS), and $40 million to $50 million for tonlamarsen, an angiotensinogen-targeted subcutaneous antisense oligonucleotide for blood pressure management in acute severe hypertension (ASH). Once again, that should fund the completion of ongoing phase 2b studies of the two drugs and the start of phase 3, with another $50 million to $60 million pledged to other R&D activities. That includes the further development of its Prolaio platform for applying AI to cardiovascular drug development, which it acquired for up to $200 million. Phase 2b data from the KINSHIP-DCM trial of danicamtiv is due in the first half of 2027, with a series of readouts from the KATALYST-AV study of ataciguat and the KARDINAL study of tonlamarsen also expected next year. Founded by former executives from MyoKardia - which was bought by Bristol Myers Squibb for $13.1 billion in 2020 - Kardigan is based in Princeton, New Jersey, with a second site in South San Francisco. Kardigan's stock is due to start trading on the Nasdaq tomorrow under the KARD ticker symbol. 18 June, 2026

Caproasia
Jun 14th, 2026
United States heart drug biotech company Kardigan Nasdaq IPO to raise $373 million at $1.4 billion valuation with expected IPO listing on 18th June 2026, co-founded in 2023 by Tassos Gianakakos.

United States heart drug biotech company Kardigan Nasdaq IPO to raise $373 million at $1.4 billion valuation with expected IPO listing on 18th June 2026, co-founded in 2023 by Tassos Gianakakos. Jun 15, 2026 15th June 2026 | Hong Kong United States heart drug biotech company Kardigan Nasdaq IPO is raising $373 million at $1.4 billion valuation, with expected IPO listing on 18th June 2026. Kardigan was co-founded in 2023 by Tassos Gianakakos. Kardigan - Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, Kardigan is developing a portfolio of medicines that modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve. Kardigan has significant East and West Coast operations and focus. "United States heart drug biotech company Kardigan Nasdaq IPO to raise $373 million at $1.4 billion valuation with expected IPO listing on 18th June 2026, co-founded in 2023 by Tassos Gianakakos"